News

Middlefield Healthcare ETF Announces Quarterly Distributions for You

Middlefield Healthcare ETF Announces Quarterly Distributions for You

Distribution Announcements for Middlefield Healthcare Dividend ETF

TORONTO, a new announcement is here from Middlefield Healthcare Dividend ETF (TSX: MHCD) that promises to pique the interest of unitholders. The Fund is excited to share the details regarding its distributions for the last quarter of the year. Ensuring unitholders are well-informed about their investments fosters transparency and trust.

Key Dates for the Upcoming Distributions

The Fund has outlined specific key dates that unitholders should take note of:

Record and Payable Dates

The distributions will be managed in a structured manner, with critical dates provided for unitholders' convenience. Information has been shared as follows:

  • Record Date: October 31, 2025
  • Payable Date: November 14, 2025
  • Distribution per Trust Unit: $0.05

Additionally:

  • Record Date: November 30, 2025
  • Payable Date: December 15, 2025
  • Distribution per Trust Unit: $0.05

Finally:

  • Record Date: December 31, 2025
  • Payable Date: January 15, 2026
  • Distribution per Trust Unit: $0.05

Investing in Trust Units

One of the remarkable features of the Middlefield Healthcare Dividend ETF is its accessibility in the market, where trust units trade on the Toronto Stock Exchange using the symbol MHCD. This makes it easier for investors to keep an eye on their investments and participate in a fund that emphasizes healthcare.

Understanding the Distribution Reinvestment Plan

Middlefield offers a Distribution Reinvestment Plan (“DRIP”) that empowers unitholders by allowing them to automatically reinvest distributions. This approach is commission-free and enhances the potential for compound growth. To enroll in this program, unitholders simply need to reach out to their investment advisor, unlocking a pathway for continuing investment growth.

About Middlefield Asset Management

Middlefield has established itself as a trusted specialist in the equity income asset management landscape since its inception in 1979. With offices in both Toronto and London, the firm has assembled a dedicated investment team that leverages active management techniques to select companies of notable quality across various sectors. Investing in proven dividend-focused strategies, Middlefield covers a broad spectrum of sectors including healthcare, energy, and real estate.

The diverse range of product offerings ensures that there’s something for every type of investor, whether through ETFs, Mutual Funds, or Closed-End Funds. The goal is to provide robust income solutions designed to meet a variety of investor needs.

Connect with Middlefield for Further Inquiries

If you’re looking for more information regarding the Middlefield Healthcare Dividend ETF or wish to learn about investment opportunities, consider visiting their official website. Engaging with knowledgeable representatives, like Nancy Tham from the Sales and Marketing Department, can provide valuable insights and guidance to help tailor your investment journey.

For inquiries, you can reach Nancy at 1.888.890.1868.

Frequently Asked Questions

What is Middlefield Healthcare Dividend ETF?

The Middlefield Healthcare Dividend ETF (TSX: MHCD) is an investment fund that focuses on healthcare-related investments, providing dividend distributions to its unitholders.

How can I benefit from the Distribution Reinvestment Plan?

The DRIP allows you to automatically reinvest your distributions without incurring any commissions, thereby benefiting from compound growth.

What are the key distribution dates to remember?

The important dates include record and payable dates for each distribution, which allow you to plan your investments effectively.

How does the investment strategy of Middlefield work?

Middlefield employs active management to select high-quality global companies across various sectors, focusing on sustainability and long-term growth.

How can I contact Middlefield for more information?

You can reach out to their Sales and Marketing Department at 1.888.890.1868 for any inquiries regarding investments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 108

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
Blue Owl Tech Faces Lawsuit Post-44% Share Dive

Updated Category News Views 59

The air's thick with tension for investors of Blue Owl Technology Finance Corp. (NYSE:OTF) as they wake up to the news of a securities class action lawsuit that's no small fry. You don’t have to look too far to see why the folks holding the bag might be steamed. We’re talking about a 44% drop in stock price since the merger with Blue Owl Technology Finance Corp....

Continue Reading
DraftKings Faces Revenue Cutback; Legal Probe Begins

Updated Category News Views 144

DraftKings' Surprising Turn of Fortune Talk about a gut punch! DraftKings (NASDAQ: DKNG) dropped a bombshell that had investors reeling. They decided to lop off a hefty slice of their revenue guidance, and trust me, those aren't small numbers we’re talking about. On November 6, they yanked their full-year 2026 revenue guidance down to $6.35 billion to $6.55 billion from...

Continue Reading
Muyuan Foods Spotlights Smart Farming at EuroTier 2026

Updated Category News Views 143

Muyuan Foods Ready to Impress at EuroTier 2026 Let's face it, folks—when you think of game-changers in pig farming, Muyuan Foods Group deserves a nod. They're not just trotting out oinkers left and right; they're steering the whole paddock with innovations in smart pig farming and green development solutions. At EuroTier 2026 in Hanover, Muyuan’s booth—J04 in Hall...

Continue Reading
Pinterest Faces Legal Probe: Investor Concerns Rise

Updated Category News Views 95

Legal Storms Gather on Pinterest's Horizon I remember a time when Pinterest was the darling of Wall Street, but here we are, staring at an investigation that's got more layers than an onion. On November 6, 2026, news broke that Kahn Swick & Foti, LLC (KSF) is sniffing around Pinterest's officers and directors. This is no small fry since KSF is steered by none other than...

Continue Reading
CassTime's AI Solution Eases Global Parts Market Strains

Updated Category News Views 112

Driving Innovation in the Auto Aftermarket When car parts become a global jigsaw puzzle, you need more than wrenches to solve it. Enter CassTime with its AI-driven 'T+D Solution'—a tangible answer to the woes of data matching and repair capability bottlenecks plaguing the automotive aftermarket worldwide. Taming the Global Parts Beast Pull back the curtain on AAPEX 2026...

Continue Reading
BlackLine's SAP Woes Spark Investor Scrutiny

Updated Category News Views 94

What Triggered This Investigation? Here we go again, folks. BlackLine's taking a hit, and it ain't pretty. They're reeling from a whopping 17.4% drop in their share price after cutting their fiscal 2026 outlook. You can bet the folks with stakes in BlackLine (NASDAQ:BL) are feeling the burn. This all comes down to a mess involving their SAP SolEx channel. Let's dive into...

Continue Reading
Interface Faces Sales Outlook Investigation Storm

Updated Category News Views 78

A Shift That Rattled Investors Interface's recent tumble in the market wasn't just a quick slip; it was a full-on somersault. The company's revised sales outlook for 2026 turned out to be a real doozy, firing up the sniffer dogs at SueWallSt into an investigation. If you've been holding onto those NASDAQ:TILE shares, this might just be the type of headache you'd want to...

Continue Reading
TEN Holdings' Q3: Cost Cuts Fuel Revenue Ambitions

Updated Category News Views 144

TEN Holdings Eyes the Future While Cleaning House If there’s one thing that catches the eye about TEN Holdings' Q3 2026 results, it’s the laser-focused cleanup of their balance sheet. They’ve slashed liabilities by 74%, up from $7.7 million at the arse end of last year to just over $2 million now. They did that by making some hard moves, hacking away at operating...

Continue Reading
Madrigal Faces Legal Scrutiny Amid Whistleblower Claims

Updated Category News Views 204

The Storm Brewing Over Madrigal Pharmaceuticals Well, folks, here we are smack dab in the middle of another roller-coaster ride in the biotech sector, and it ain't pretty. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is in hot water with some serious allegations thrown their way. The company is now under investigation by Kessler Topaz Meltzer & Check, LLP, a top-notch...

Continue Reading

Top 5 Most Recently Viewed Articles

Honoring Thyroid Cancer Survivors: Expert Care Makes a Difference

Updated Category News Views 139

Celebrating Thyroid Cancer Survivors: A Day of Recognition The Clayman Thyroid Center at the Hospital for Endocrine Surgery is excited to honor Thyroid Cancer Survivor's Day, a time dedicated to celebrating the incredible courage and tenacity of individuals who have conquered thyroid cancer. This illness is one of the fastest-growing cancer diagnoses in the nation,...

Continue Reading
Market Dynamics: Futures Flat Amid Fed Rate Speculations

Updated Category News Views 109

Futures Show Stability Amid Uncertain Federal Reserve Actions As traders assess the market landscape, U.S. stock index futures are showing a steady performance. This week, there's a heightened concern surrounding potential changes in interest rates by the Federal Reserve. Investors are on edge, eagerly anticipating the results of the Fed's forthcoming meeting. Market...

Continue Reading
Alvopetro Energy's Q3 2025 Update on Sales and Expansion Plans

Updated Category News Views 218

Alvopetro Energy Ltd. Reports on September Sales Volumes Alvopetro Energy Ltd. (TSXV: ALV, OTCQX: ALVOF) has released its September sales volumes and noteworthy updates concerning its operations. The company has announced impressive sales volumes averaging 2,231 barrels of oil equivalent per day (boepd) during that month, reflecting its continued operational strength...

Continue Reading
Bybit Web3 Launches Babylon Season with Exciting Opportunities

Updated Category News Views 86

Bybit Web3 Launches Babylon Season with Exciting Opportunities Bybit Web3, a key component of the world’s second-largest cryptocurrency exchange, is excited to introduce its innovative initiative called Babylon Season. This project aims to enhance access, diversity, and interoperability within the Web3 ecosystem. As the BTC market continues to evolve, Bybit Web3 is...

Continue Reading
Icotrokinra Shows Promising Results in Ulcerative Colitis Study

Updated Category News Views 303

Icotrokinra Shows Promising Results in Ulcerative Colitis Study Icotrokinra has demonstrated profound outcomes in addressing ulcerative colitis (UC), as shown in the recent Phase 2b ANTHEM-UC study. This investigational medication, designed as a once-daily pill, has shown a combination of effective therapeutic benefit and a favorable safety profile, maintaining its...

Continue Reading